Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL). Group 1 received vorinostat 400 mg daily, group 2 received vorinostat 300 mg twice daily for 3 days with 4 days...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Duvic, Madeleine, Talpur, Rakshandra, Ni, Xiao, Zhang, Chunlei, Hazarika, Parul, Kelly, Cecilia, Chiao, Judy H., Reilly, John F., Ricker, Justin L., Richon, Victoria M., Frankel, Stanley R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2007
Soggetti:
Clinical Trials and Observations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC1785068/
https://ncbi.nlm.nih.gov/pubmed/16960145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-06-025999
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi